We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended September 2023, Jazz Pharmaceuticals (JAZZ - Free Report) reported revenue of $972.14 million, up 3.4% over the same period last year. EPS came in at $4.84, compared to $5.17 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $969.47 million, representing a surprise of +0.28%. The company delivered an EPS surprise of -1.22%, with the consensus EPS estimate being $4.90.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Royalties and contract revenues: $33.74 million versus $20.79 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +590.6% change.
Revenues- Product sales, net: $938.40 million versus the nine-analyst average estimate of $946.88 million. The reported number represents a year-over-year change of +0.3%.
Total revenues- Oxybate- Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: $331.63 million versus $336.92 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +29.6% change.
Total revenues- Neuroscience- Epidiolex/Epidyolex: $213.71 million compared to the $219.08 million average estimate based on eight analysts. The reported number represents a change of +8.9% year over year.
Total revenues- Neuroscience- Sativex: $4.63 million versus the eight-analyst average estimate of $4.18 million. The reported number represents a year-over-year change of +43.7%.
Total revenues- Oncology- Defitelio(defibrotide)/defibrotide: $47.73 million versus $49.26 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
Total revenues- Oncology- Vyxeos: $29.83 million versus the eight-analyst average estimate of $34.10 million. The reported number represents a year-over-year change of -0.8%.
Total revenues- Oncology- Zepzelca (lurbinectedin): $77.99 million compared to the $74.03 million average estimate based on eight analysts. The reported number represents a change of +10.9% year over year.
Total revenues- Other: $2.91 million compared to the $1.85 million average estimate based on eight analysts. The reported number represents a change of +190.4% year over year.
Total revenues- Oxybate- Xyrem: $125.11 million compared to the $125.84 million average estimate based on eight analysts. The reported number represents a change of -51.1% year over year.
Total revenues- Oncology- Rylaze: $104.86 million compared to the $102.26 million average estimate based on seven analysts.
Total revenues- Total Oncology: $260.41 million versus $260.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16.6% change.
Shares of Jazz have returned +2.6% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
For the quarter ended September 2023, Jazz Pharmaceuticals (JAZZ - Free Report) reported revenue of $972.14 million, up 3.4% over the same period last year. EPS came in at $4.84, compared to $5.17 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $969.47 million, representing a surprise of +0.28%. The company delivered an EPS surprise of -1.22%, with the consensus EPS estimate being $4.90.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Royalties and contract revenues: $33.74 million versus $20.79 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +590.6% change.
- Revenues- Product sales, net: $938.40 million versus the nine-analyst average estimate of $946.88 million. The reported number represents a year-over-year change of +0.3%.
- Total revenues- Oxybate- Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: $331.63 million versus $336.92 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +29.6% change.
- Total revenues- Neuroscience- Epidiolex/Epidyolex: $213.71 million compared to the $219.08 million average estimate based on eight analysts. The reported number represents a change of +8.9% year over year.
- Total revenues- Neuroscience- Sativex: $4.63 million versus the eight-analyst average estimate of $4.18 million. The reported number represents a year-over-year change of +43.7%.
- Total revenues- Oncology- Defitelio(defibrotide)/defibrotide: $47.73 million versus $49.26 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
- Total revenues- Oncology- Vyxeos: $29.83 million versus the eight-analyst average estimate of $34.10 million. The reported number represents a year-over-year change of -0.8%.
- Total revenues- Oncology- Zepzelca (lurbinectedin): $77.99 million compared to the $74.03 million average estimate based on eight analysts. The reported number represents a change of +10.9% year over year.
- Total revenues- Other: $2.91 million compared to the $1.85 million average estimate based on eight analysts. The reported number represents a change of +190.4% year over year.
- Total revenues- Oxybate- Xyrem: $125.11 million compared to the $125.84 million average estimate based on eight analysts. The reported number represents a change of -51.1% year over year.
- Total revenues- Oncology- Rylaze: $104.86 million compared to the $102.26 million average estimate based on seven analysts.
- Total revenues- Total Oncology: $260.41 million versus $260.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16.6% change.
View all Key Company Metrics for Jazz here>>>Shares of Jazz have returned +2.6% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.